Outcomes of Re-Switching Anti–Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration
In cases where brolucizumab treatment was discontinued due to IOI and switched back to other anti-VEGF agents, the anatomical response was insufficient, indicating the need for alternative treatment options.
Authors
- Yousin Suh (ORCID: https://orcid.org/0000-0002-9275-6192)
- Min Seok Kim (ORCID: https://orcid.org/0000-0001-7092-5429)
- Seok Hee Lee (ORCID: https://orcid.org/0000-0002-4656-1618)
Institutions
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
Publication Details
- Journal
- Korean Journal of Ophthalmology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3341/kjo.2025.0008
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Seoul National University Bundang Hospital
- Seoul National University